Pulmonary Fibrosis News Home | Pulmonary Fibrosis …
WEBAvalyn Pharma has started a Phase 2b clinical trial testing the safety and efficacy of AP01, its investigational inhaled formulation of pirfenidone, in adults with progressive pulmonary fibrosis (PF). The MIST trial …
Ofev, Esbriet Seen to Lengthen Life for IPF Patients With 'Mild'...
WEBNov 4, 2020 · Researchers with The University of Manchester conducted an analysis using real-world data to assess how use of these two medications affect lung function and …
Esbriet, Ofev Found to Benefit IPF Patients in Clinical …
WEBApr 6, 2021 · Two approved anti-fibrotics are proving to be safe and effective in treating idiopathic pulmonary fibrosis (IPF), a study with real …
- Occupation: Science Writer
- Estimated Reading Time: 4 mins
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis …
WEBRecent Posts. Immune cells separate IPF, fibrotic hypersensitivity pneumonitis September 6, 2024; Tales of 2 women, both named Melissa, on their IPF journeys September 3, 2024; Patient journeys highlighted …
Oral BMS-986278 slows lung decline in progressive PF, …
WEBSep 25, 2023 · These findings are consistent with previously reported data from a group of idiopathic pulmonary fibrosis (IPF) patients also participating in the clinical trial, whose lung function decline decreased …
IPF Patients Live Longer on Ofev Compared with …
WEBApr 16, 2019 · The analysis included data collected from a total of 1,126 IPF patients (mean age of 66.9 years), who were treated twice daily with 150 mg of Ofev, and 565 patients treated with a placebo. Participants …
BMS-986278 declared breakthrough therapy for progressive PF
WEBOct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) …
First Patient Enrolled in Phase 3 Trial Testing BI 1015550
WEBOct 28, 2022 · by Steve Bryson, PhD October 28, 2022. Boehringer Ingelheim has enrolled the first patient in FIBRONEER-IPF, a Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of BI 1015550, …
Saracatinib as Effective, or Superior to Ofev, Esbriet in …
WEBAug 30, 2022 · Saracatinib worked as well or better than Ofev or Esbriet at reducing tissue scarring, or fibrosis, in cell and animal models of IPF, a study showed.. The oral therapy was identified as an IPF treatment …
Study: ENV-101 improves IPF lung function, reverses fibrosis
WEBby Andrea Lobo June 7, 2024. Endeavor BioMedicines ’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis …
Skip to content